当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.

Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.

Abstract：

:Endocrine therapy is an important therapeutic approach for the treatment of oestrogen receptor (ER)-positive breast cancer. However, a number of these endocrine therapies can fail when the tumour loses its ER expression during treatment. To date, few studies have explored the potential clinical significance of traditional Chinese medicine in inducing the reversal of resistance to endocrine therapy in breast cancers. We used the ERα-negative MCF7 breast cancer cell line to create a tamoxifen (TAM)-resistant cell line, MCF7/TAM cells. After treating MCF7/TAM cells with ELE to induce the re-expression of ERα, we investigated the role and molecular mechanisms by which elemene (ELE) promotes the reversal of resistance to endocrine therapy. We discovered that treatment with 10 μg/ml ELE restored the sensitivity of MCF7/TAM cells to TAM. RT-PCR analysis revealed that ELE treatment upregulated ERα mRNA levels in MCF7/TAM cells, and immunohistochemistry confirmed the upregulation of ERα expression. Western blot analysis revealed that ELE treatment decreased the protein expression levels of Ras, MEK1/2 and p-ERK1/2 in MCF7/TAM cells. The loss of ERα expression was the primary reason for TAM resistance in MCF7 cells. The ELE-induced reversal of TAM resistance was mediated by the upregulation of ERα mRNA and the re-expression of ERα through the MAPK pathway.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Zhang B,Zhang X,Tang B,Zheng P,Zhang Y

doi

10.1007/s10549-012-2263-6

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

399-406

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

136

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

    abstract：:To assess the impact of patient-provider communication on adherence to tamoxifen (TAM) and aromatase inhibitors (AIs) 36 months after breast cancer (BC) diagnosis in a low-income population of women. California statewide surveys were conducted among 921 low-income women with BC at 6, 18, and 36 months after BC diagnos...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2387-8

    authors： Liu Y,Malin JL,Diamant AL,Thind A,Maly RC

    更新日期：2013-02-01 00:00:00

  • C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

    abstract：:To investigate the expression levels of CXCL10 and CXCR3 in tumors from breast cancer patients randomized to adjuvant tamoxifen treatment or no endocrine treatment, in order to further study the connection to prognosis and prediction of tamoxifen treatment outcome. Immunohistochemistry on tissue microarrays from 912 b...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-014-2933-7

    authors： Hilborn E,Sivik T,Fornander T,Stål O,Nordenskjöld B,Jansson A

    更新日期：2014-05-01 00:00:00

  • Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.

    abstract：:Previous studies showing the presence of antibodies against tumor-associated antigens in healthy individuals suggest that antibody-dependent cell cytotoxicity (ADCC) might play a role in the development of breast cancer. We hypothesized that functional polymorphisms in fragment c gamma receptor (FcgR) genes were assoc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1109-3

    authors： Iwasaki M,Shimada N,Kasuga Y,Yokoyama S,Onuma H,Nishimura H,Kusama R,Hamada GS,Nishimoto IN,Iyeyasu H,Motola J Jr,Laginha FM,Anzai R,Tsugane S

    更新日期：2011-04-01 00:00:00

  • Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.

    abstract：:Brain gray matter alterations have been reported in cross-sectional magnetic resonance imaging (MRI) studies of breast cancer patients after cancer treatment. Here we report the first prospective MRI study of women undergoing treatment for breast cancer, with or without chemotherapy, as well as healthy controls. We hy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1088-4

    authors： McDonald BC,Conroy SK,Ahles TA,West JD,Saykin AJ

    更新日期：2010-10-01 00:00:00

  • Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?

    abstract：PURPOSE:We sought to determine if bioimpedance spectroscopy (BIS) measurements can accurately assess changes in breast cancer-related lymphedema (BCRL) in patients undergoing lymphovenous bypass (LVB). METHODS:Patients undergoing LVB for BCRL refractory to conservative treatment from 1/2015 to 12/2018 were identified ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-06059-6

    authors： Sutherland A,Wagner JL,Korentager S,Butterworth J,Amin AL,Balanoff CR,Hangge A,Larson KE

    更新日期：2021-01-04 00:00:00

  • Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

    abstract：:Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural regio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1916-1

    authors： Lipscomb J,Gillespie TW,Goodman M,Richardson LC,Pollack LA,Ryerson AB,Ward KC

    更新日期：2012-05-01 00:00:00

  • Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons.

    abstract：:Intraoperative radiotherapy with electrons (ELIOT) after conservative surgery for breast carcinoma was introduced at the IEO in 1999 as a research programme. The results on 1,822 patients treated from January 2000 to December 2008 are reported. Women with unicentric primary breast carcinoma of less than 2.5 cm in the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1115-5

    authors： Veronesi U,Orecchia R,Luini A,Galimberti V,Zurrida S,Intra M,Veronesi P,Arnone P,Leonardi MC,Ciocca M,Lazzari R,Caldarella P,Rotmensz N,Sangalli C,Sances D,Maisonneuve P

    更新日期：2010-11-01 00:00:00

  • Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.

    abstract：PURPOSE:In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1-T2 cN0 early breast cancer and 1-2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05876-z

    authors： Riedel F,Heil J,Feisst M,Moderow M,von Au A,Domschke C,Michel L,Schaefgen B,Golatta M,Hennigs A

    更新日期：2020-11-01 00:00:00

  • A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

    abstract：:A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer. To determine the tolerability and efficacy of increasing doses of megestrol acetate in the treatment of metastatic breast cancer, we conducted a phase I/II study among 57 patients. Three patients...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01990033

    authors： Parnes HL,Abrams JS,Tchekmedyian NS,Tait N,Aisner J

    更新日期：1991-08-01 00:00:00

  • Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.

    abstract：PURPOSE:Triple-negative breast cancers (TNBC) are aggressive tumours that exhibit abundant lymphoid infiltrates which modulate tumour behaviour. Recent findings suggest that TNBC with higher densities of plasma cells are associated with a favourable prognosis, and tertiary lymphoid structures (TLS) have prognostic sign...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05548-y

    authors： Seow DYB,Yeong JPS,Lim JX,Chia N,Lim JCT,Ong CCH,Tan PH,Iqbal J

    更新日期：2020-04-01 00:00:00

  • Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.

    abstract：PURPOSE:To examine DNA methylation as a mechanism linking diet, physical activity, weight status, and breast cancer risk. METHODS:Insufficiently active women of varying weight status, without a history of cancer, completed a maximal exercise test, clinical measurement of height and weight, and a dietary intake measure...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4573-1

    authors： Gillman AS,Gardiner CK,Koljack CE,Bryan AD

    更新日期：2018-02-01 00:00:00

  • T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.

    abstract：PURPOSE:T-box transcription factor 21 (T-bet), which is the master regulator of effector T-cell activation, is derived by stimulation of T-cell receptors. In this study, we focused on T-bet and examined the function of activated T cells. METHODS:This study included 242 patients with primary triple-negative breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05256-2

    authors： Mori H,Kubo M,Kai M,Yamada M,Kurata K,Kawaji H,Kaneshiro K,Osako T,Nishimura R,Arima N,Okido M,Kishimoto J,Oda Y,Nakamura M

    更新日期：2019-08-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract：:Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-011-1759-9

    authors： Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期：2012-04-01 00:00:00

  • Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.

    abstract：:Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast can...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9935-2

    authors： Shien T,Shimizu C,Seki K,Shibata T,Hojo T,Ando M,Kohno T,Katsumata N,Akashi-Tanaka S,Kinoshita T,Fujiwara Y

    更新日期：2009-01-01 00:00:00

  • The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.

    abstract：PURPOSE:Triple-negative breast cancer (TNBC)/basal-like breast cancer (BLBC) is a highly aggressive form of breast cancer. We previously reported that a small molecule agonist ligand for the orphan nuclear receptor estrogen-related receptor beta (ERRβ or ESRRB) has growth inhibitory and anti-mitotic activity in TNBC ce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05485-5

    authors： Fernandez AI,Geng X,Chaldekas K,Harris B,Duttargi A,Berry VL,Berry DL,Mahajan A,Cavalli LR,Győrffy B,Tan M,Riggins RB

    更新日期：2020-02-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract：:Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1946-8

    authors： Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期：2012-07-01 00:00:00

  • Differential gene expression profile in breast cancer-derived stromal fibroblasts.

    abstract：BACKGROUND:Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis. While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation. MATERIALS AND METHODS:...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9725-2

    authors： Singer CF,Gschwantler-Kaulich D,Fink-Retter A,Haas C,Hudelist G,Czerwenka K,Kubista E

    更新日期：2008-07-01 00:00:00

  • Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodeling.

    abstract：:Psoriasin (S100A7) is a calcium-binding protein that has shown to be highly expressed in high-grade ductal carcinoma in situ (DCIS) and a subset of invasive breast cancers. However, its role in invasion and metastasis is not very well known. In this study, we have shown that S100A7 differentially regulates epidermal g...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2491-4

    authors： Sneh A,Deol YS,Ganju A,Shilo K,Rosol TJ,Nasser MW,Ganju RK

    更新日期：2013-04-01 00:00:00

  • Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

    abstract：:Our aim was to develop an accurate diagnostic system using gene expression analysis by means of DNA microarray for prognosis of node-negative and estrogen receptor (ER)-positive breast cancer patients in order to identify a subset of patients who can be safely spared adjuvant chemotherapy. A diagnostic system comprisi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1145-z

    authors： Naoi Y,Kishi K,Tanei T,Tsunashima R,Tominaga N,Baba Y,Kim SJ,Taguchi T,Tamaki Y,Noguchi S

    更新日期：2011-08-01 00:00:00

  • Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

    abstract：:A limited number of studies have associated adjuvant chemotherapy with structural brain changes. These studies had small sample sizes and were conducted shortly after cessation of chemotherapy. Results of these studies indicate local gray matter volume decrease and an increase in white matter lesions. Up till now, it ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1888-1

    authors： Koppelmans V,de Ruiter MB,van der Lijn F,Boogerd W,Seynaeve C,van der Lugt A,Vrooman H,Niessen WJ,Breteler MM,Schagen SB

    更新日期：2012-04-01 00:00:00

  • Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

    abstract：PURPOSE:To investigate the discordance between original and central laboratories in estrogen receptor (ER) status, in tumors originally deemed to be ER-negative, and in HER2 status in a diverse population-based sample. METHODS:In a follow-up study of 1785 women with Stage I-III breast cancer diagnosed between 2005 and...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4061-z

    authors： Griggs JJ,Hamilton AS,Schwartz KL,Zhao W,Abrahamse PH,Thomas DG,Jorns JM,Jewell R,Saber ME,Haque R,Katz SJ

    更新日期：2017-01-01 00:00:00

  • Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis.

    abstract：:Progression of breast cancer from an estrogen-dependent, slowly growing tumor amenable to tamoxifen treatment to an aggressive, metastatic, estrogen-independent phenotype has been mimicked by the transfection of MCF-7 breast carcinoma cells with fibroblast growth factors 1 or 4. FGF-transfected cells are aggressively ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806082

    authors： McLeskey SW,Zhang L,Kharbanda S,Kurebayashi J,Lippman ME,Dickson RB,Kern FG

    更新日期：1996-01-01 00:00:00

  • Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.

    abstract：PURPOSE:Mitochondrial unfolding protein are abundant in breast cancer cells, but the mechanism by which breast cancer cells resist apoptosis is still not fully elucidated. In this study, we explored the role of mitochondrial unfolded protein response (mtUPR)-related proteins in four types of breast cancer tissues. MET...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05729-9

    authors： Chen FM,Huang LJ,Ou-Yang F,Kan JY,Kao LC,Hou MF

    更新日期：2020-08-01 00:00:00

  • Ethnic differences in risk perception among women at increased risk for breast cancer.

    abstract：:There has been increasing interest in the role of cultural and ethnic factors in breast cancer risk perceptions and screening practices. This study examined ethnic differences in breast cancer risk perception in 112 African American and 224 white women ages 35 and older who had at least one first-degree relative diagn...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/BF01806000

    authors： Hughes C,Lerman C,Lustbader E

    更新日期：1996-01-01 00:00:00

  • Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

    abstract：:Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805741

    authors： Nagasawa H,Aoki M,Sakagami N,Ishida M

    更新日期：1988-09-01 00:00:00

  • Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.

    abstract：:Whether or not breast cancer can be a feature of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has been debated. In order to clarify if defective mismatch repair (MMR) may indeed play a role in breast cancer, we used the Danish HNPCC register to identify all breast cancers that occurred in MMR gene mu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0449-3

    authors： Jensen UB,Sunde L,Timshel S,Halvarsson B,Nissen A,Bernstein I,Nilbert M

    更新日期：2010-04-01 00:00:00

  • Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

    abstract：:Since our previous findings had indicated that the androgenic steroid medroxyprogesterone acetate (MPA) exerts potent inhibitory effects on 7,12-dimethylbenz(a)anthracene (DMBA)-induced tumor growth, we have studied the effect of low doses of MPA released from Depo-Provera and from 50:50 poly[DL-lactide-co-glycolide] ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01961245

    authors： Li S,Lepage M,Mérand Y,Bélanger A,Labrie F

    更新日期：1992-01-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract：:Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006190820231

    authors： Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期：1999-02-01 00:00:00

  • Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.

    abstract：PURPOSE:Dysregulation of HER2 signaling pathway in breast cancer is well documented. Our bioinformatics analysis predicted hsa-miR-512-3p (miR-512-3p) as a bona fide regulator of HER2 as well as HER3, PIK3R2, and AKT1 genes. Then, we intended to examine the effect of miR-512-3p on the predicted target genes that are in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05937-3

    authors： Mohamadzade Z,Mahjoubi F,Soltani BM

    更新日期：2021-01-01 00:00:00

  • Design of preparative regimens for stem cell transplantation in breast cancer.

    abstract：:We have evaluated tandem cycles of a tri-drug combination, termed CVP (cyclophosphamide, etoposide [VP-16], and cisplatin [Platinol]), at four levels in more than 300 patients with various types of tumors. Tandem CVP appears to be at least therapeutically equivalent to alternatives. A second potentially non-cross-resi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00668354

    authors： Spitzer G,Adkins D,Dunphy F,Petruska P,Spencer V,Velasquez W

    更新日期：1993-01-01 00:00:00